×
App Icon
The Standard e-Paper
Join Thousands Daily
★★★★ - on Play Store
Download App

Kemri: TB vaccine trials promising, treatment period to reduce

Tuberculosis remains a leading killer disease in Kenya. [Courtesy]

The Kenya Medical Research Institute (KEMRI) has said that the clinical trials of its Tuberculosis (TB) vaccine for adults and children is promising.

Once the tests are conclusive, KEMRI says it would seek approval from the World Health Organization (WHO) to roll out the vaccine for public use.

Premium Article

Get Full Access for Ksh299/Week.

Bold Reporting Takes Time, Courage and Investment. Stand With Us.
Continue Reading  →
What you get
  • Unlimited access to all premium content
  • Ad-free browsing experience
  • Mobile-optimised reading
  • Weekly newsletters & digests
Pay via
M - PESA
VISA
Airtel Money
Secure Payments Kenya's most trusted newsroom since 1902